We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Roche Holding Ag | LSE:0QQ6 | London | Ordinary Share | CH0012032113 | ROCHE HOLDING ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| 0.00 | 0.00% | 229.20 |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 438 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 60.5B | 8.28B | - | N/A | 0 |
| Date | Time | Source | Headline |
|---|---|---|---|
| 12/2/2025 | 16:45 | UKREG | FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal.. |
| 07/2/2025 | 08:45 | UKREG | New England Journal of Medicine publishes new data for Roche’s.. |
| 04/2/2025 | 16:45 | UKREG | FDA approves Roche’s Susvimo as the first and only continuous delivery.. |
| 31/1/2025 | 16:45 | UKREG | Roche receives FDA approval for the first companion diagnostic to identify.. |
| 30/1/2025 | 06:00 | UKREG | [Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche erzielt starkes Jahresergebnis.. |
| 30/1/2025 | 06:00 | UKREG | [Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024.. |
| 29/1/2025 | 06:00 | UKREG | Change to the Roche Enlarged Corporate Executive Committee |
| 28/1/2025 | 06:00 | UKREG | Roche’s Itovebi demonstrated statistically significant and clinically.. |
| 27/1/2025 | 06:00 | UKREG | Roche announces new results from EMBARK demonstrating significant sustained.. |
| 22/1/2025 | 06:00 | UKREG | Roche receives FDA clearance with CLIA waiver for cobas® liat molecular.. |
1 Year Roche Chart |
Intraday Roche Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
